582 – Initiating Long-Acting Lenacapavir in a Cohort of PWH With High Baseline Resistance: A Case Series
Background In 2021, the first long-acting (LA) ART regimen cabotegravir/rilpivirine (CAB/RPV) was approved for people with HIV (PWH) with virologic suppression (VS). Demonstration projects show high rates of achieving VS among PWH with viremia at initiation, leading to US guidelines permitting this approach in 2024. Pre-existing resistance to either CAB or RPV reduces the effectiveness…